These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28494536)

  • 1. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
    Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
    Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
    Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
    Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
    J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
    Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
    Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative CEA values in metastatic colorectal carcinoma and the likelihood of complete chemotherapy response.
    Tomasevic Z; Jelic S; Nikolic L; Filipovic I; Stamatovic L; Radosavljevic D
    Int J Biol Markers; 2003; 18(1):28-32. PubMed ID: 12699060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases.
    van Kessel CS; Samim M; Koopman M; van den Bosch MA; Borel Rinkes IH; Punt CJ; van Hillegersberg R
    Eur J Cancer; 2013 Jul; 49(11):2486-93. PubMed ID: 23692811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases.
    Neofytou K; Giakoustidis A; Neves MC; Morrison D; Giakoustidis D; Khan AZ; Stebbing J; Mudan S
    Langenbecks Arch Surg; 2017 Jun; 402(4):599-605. PubMed ID: 27043945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
    Öztürk H
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of half-life of carcinoembryonic antigen (CEA) in prognosis prediction of colorectal cancer patients with preoperatively elevated CEA.
    Yuan SQ; Zhou ZW; Wan DS; Chen G; Lu ZH; Wang GQ; Pan ZZ
    Ai Zheng; 2008 Jun; 27(6):612-7. PubMed ID: 18570735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
    Chiu KWH; Lam KO; An H; Cheung GTC; Lau JKS; Choy TS; Lee VHF
    BMC Cancer; 2018 Jul; 18(1):776. PubMed ID: 30064385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
    Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
    Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
    Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
    Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
    Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
    Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
    Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.